Neuphoria Therapeutics Inc (NEUP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.77+0.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NEUP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Finalize the all-share merger with Scancell, complete related financing, and list the combined company on Nasdaq by late Q4 2026.
Newly stated in 2026-Q3. Management announced the merger with Scancell and related US Listing Transactions are expected to complete in late Q4 2026. This is a new strategic priority with no prior quarters stated. The financials show no revenue or operating income impact yet, consistent with the transaction pending completion.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The US Listing Transactions are expected to complete concurrently in late Q4 2026 subject to customary closing conditions.”
Secure approximately $79 million through private placement, UK placing, retail offer, and debt financing to fund registrational Phase 3 study and extend cash runway into 2029.
Newly stated in 2026-Q3. Management disclosed plans to raise about $79.1 million through multiple financing sources to fund the Phase 3 trial and extend cash runway into 2029. Financials show negative operating income and net income in recent quarters, indicating ongoing need for financing. The priority is consistent with the current financial situation.
“Financing to fund the global registrational Phase 3 trial for lead programme... expected to extend the Group’s cash runway into 2029.”
Advance the lead asset iSCIB1+ through registrational Phase 3 study with key clinical milestones including primary readout in H2 2028.
Newly stated in 2026-Q3. Management emphasized advancing iSCIB1+ through Phase 3 with a primary readout expected in H2 2028. No revenue or operating income from this asset is yet reported, consistent with ongoing clinical development. The priority aligns with the financing plans and clinical milestones.
“Financing will provide capital to conduct the registrational Phase 3 study for iSCIB1+ including primary readout in H2 2028.”
Provide Neuphoria stockholders CVRs for potential future cash payments from partnered assets, IP monetization, and Australian R&D tax credit.
Newly stated in 2026-Q3. Management introduced CVRs to provide Neuphoria stockholders potential future payments from partnered assets and IP monetization. This is a new capital allocation mechanism tied to the merger. Financials do not yet reflect monetization proceeds, consistent with the early stage of this priority.
“Neuphoria stockholders will receive CVRs representing rights to future conditional cash payments based on milestones and monetisation.”
Over the trailing year it converted 0.84x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
16 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.